Literature DB >> 32198140

Proinflammatory S100A8 Induces PD-L1 Expression in Macrophages, Mediating Tumor Immune Escape.

Zhengshuo Li1,2,3, Jing Wang4,5, Xuemei Zhang2,6, Peishan Liu2, Xiaoyue Zhang2, Jia Wang2, Xiang Zheng2, Lingyu Wei2, Qiu Peng2, Can Liu2, Qun Yan1,7, Shourong Shen4, Xiayu Li4, Jian Ma8,2,3,4.   

Abstract

S100A8 is a damage-associated molecular pattern protein released by monocytes, playing a decisive role in the development of inflammation. Nonresolving inflammation is viewed as a driving force in tumorigenesis, and its role in tumor immune escape also attracted attentions. PD-1/PD-L1 axis is a critical determinant of physiological immune homeostasis, and anti-PD-1 or PD-L1 therapy has becoming the most exciting field of oncology. Multiple regulation mechanisms have been contributed to PD-L1 expression modulation including inflammatory mediators. In this study we reported that S100A8 significantly induced PD-L1 expression in monocytes/macrophages but not in tumor cells. S100A8 induced PD-L1 transcription through the TLR4 receptor and multiple crucial pathways of inflammation process. S100A8 modulated the histone modification of the PD-L1 promoter in monocytes/macrophages. S100A8-pretreated macrophages had immunosuppressive function and attenuated the antitumor ability of CTLs both in vitro and in vivo. A highly positive correlation existed between S100A8 expression and PD-L1 expression in human cancer specimens. To our knowledge, our study uncovers a novel molecular mechanism for regulating PD-L1 transcription by an inflammatory mediator S100A8, and reveals the importance of comprehensive understanding the role of inflammation in tumorigenesis as well as in tumor immune escape.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Year:  2020        PMID: 32198140     DOI: 10.4049/jimmunol.1900753

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.

Authors:  Zhaoli Tan; Chunyan Yue; Shoujian Ji; Chuanhua Zhao; Ru Jia; Yun Zhang; Rongrui Liu; Da Li; Qian Yu; Ping Li; Zhiyuan Hu; Yanlian Yang; Jianming Xu
Journal:  Oncologist       Date:  2021-09-28

Review 2.  Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape.

Authors:  Qinghua Wu; Li You; Eugenie Nepovimova; Zbynek Heger; Wenda Wu; Kamil Kuca; Vojtech Adam
Journal:  J Hematol Oncol       Date:  2022-06-03       Impact factor: 23.168

3.  Alarm Signal S100-Related Signature Is Correlated with Tumor Microenvironment and Predicts Prognosis in Glioma.

Authors:  Lin-Jian Wang; Peipei Lv; Yongli Lou
Journal:  Dis Markers       Date:  2022-05-10       Impact factor: 3.464

4.  A Dynamic Transcriptome Map of Different Tissue Microenvironment Cells Identified During Gastric Cancer Development Using Single-Cell RNA Sequencing.

Authors:  Honghao Yin; Rui Guo; Huanyu Zhang; Songyi Liu; Yuehua Gong; Yuan Yuan
Journal:  Front Immunol       Date:  2021-10-21       Impact factor: 7.561

5.  Predictive value of proteomic markers for advanced rectal cancer with neoadjuvant chemoradiotherapy.

Authors:  Hanyang Wang; Dengbo Ji; Huifang Tian; Zhaoya Gao; Can Song; Jinying Jia; Xinxin Cui; Lijun Zhong; Jing Shen; Jin Gu
Journal:  BMC Cancer       Date:  2022-08-09       Impact factor: 4.638

6.  Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression.

Authors:  Zhengshuo Li; Xiaoyue Zhang; Can Liu; Qiu Peng; Yangge Wu; Yuqing Wen; Run Zheng; Qun Yan; Jian Ma
Journal:  J Innate Immun       Date:  2021-11-01       Impact factor: 7.111

7.  The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells.

Authors:  Pin-Jui Kung; Ting-Yu Lai; Jerry Cao; Li-Chung Hsu; Tsai-Chen Chiang; Pu Ou-Yang; Ching-Yi Tsai; Yi-Fen Tsai; Chih-Wen Lin; Chien-Chia Chen; Meng-Kun Tsai; Yu-Wen Tien; Chih-Yuan Lee
Journal:  Cancer Immunol Immunother       Date:  2021-08-10       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.